MA50441A - Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) - Google Patents

Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)

Info

Publication number
MA50441A
MA50441A MA050441A MA50441A MA50441A MA 50441 A MA50441 A MA 50441A MA 050441 A MA050441 A MA 050441A MA 50441 A MA50441 A MA 50441A MA 50441 A MA50441 A MA 50441A
Authority
MA
Morocco
Prior art keywords
fibrosan
pneumopathies
ild
treatment
active agents
Prior art date
Application number
MA050441A
Other languages
English (en)
Inventor
Franziska Elena Herrmann
Peter Nickolaus
Stefan Ludwig Michael Wollin
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA50441A publication Critical patent/MA50441A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050441A 2017-10-23 2018-10-12 Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) MA50441A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17197719 2017-10-23

Publications (1)

Publication Number Publication Date
MA50441A true MA50441A (fr) 2020-09-02

Family

ID=60162029

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050441A MA50441A (fr) 2017-10-23 2018-10-12 Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)

Country Status (26)

Country Link
US (4) US11406638B2 (fr)
EP (2) EP4603094A2 (fr)
JP (1) JP7196169B2 (fr)
KR (2) KR20250172732A (fr)
CN (1) CN111278442B (fr)
AU (2) AU2018357775B2 (fr)
BR (1) BR112020003973A2 (fr)
CA (1) CA3079299A1 (fr)
CL (1) CL2020000627A1 (fr)
DK (1) DK3700529T3 (fr)
EA (1) EA202090977A1 (fr)
ES (1) ES3041129T3 (fr)
FI (1) FI3700529T3 (fr)
HR (1) HRP20251042T1 (fr)
HU (1) HUE072914T2 (fr)
IL (2) IL273169B2 (fr)
LT (1) LT3700529T (fr)
MA (1) MA50441A (fr)
MX (1) MX2020004173A (fr)
PH (1) PH12020550452A1 (fr)
PL (1) PL3700529T3 (fr)
PT (1) PT3700529T (fr)
RS (1) RS67241B1 (fr)
SI (1) SI3700529T1 (fr)
TW (1) TWI700088B (fr)
WO (1) WO2019081235A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230201144A1 (en) * 2020-05-29 2023-06-29 Novomedix, Llc Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease
CN113116904B (zh) * 2021-03-23 2022-11-29 深圳市泰力生物医药有限公司 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用
EP4494701A3 (fr) * 2021-12-09 2025-04-02 Boehringer Ingelheim International GmbH Nouvelles combinaisons thérapeutiques pour le traitement de maladies pulmonaires interstitielles fibrosantes progressives
EP4426307B1 (fr) * 2021-12-09 2025-07-02 Boehringer Ingelheim International GmbH Nouvelle composition pharmaceutique orale et schéma posologique pour le traitement de la maladie pulmonaire interstitielle fibrosante progressive
IL317209A (en) * 2022-05-28 2025-01-01 Avalyn Pharma Inc Nintedanib and combined dry powder preparations Nintedanib and uses
US20250326765A1 (en) * 2022-06-02 2025-10-23 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
WO2023241683A1 (fr) * 2022-06-16 2023-12-21 武汉人福创新药物研发中心有限公司 Composé hétérocyclique contenant de l'azote agissant en tant qu'inhibiteur de pde4b
IL318673A (en) * 2022-08-09 2025-03-01 Xizang Haisco Pharmaceutical Co Ltd PDE4B inhibitor and its use
WO2024068386A1 (fr) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Utilisation de biomarqueurs dans le traitement d'états fibrotiques avec inhibiteur de la pde4b
KR20240159339A (ko) * 2023-04-28 2024-11-05 한국원자력의학원 폐섬유화 예방 또는 치료를 위한 다코미티닙 및 닌테다닙의 병용 요법
KR20240159340A (ko) * 2023-04-28 2024-11-05 한국원자력의학원 폐섬유화 예방 또는 치료를 위한 펙시다티닙 및 닌테다닙의 병용 요법
WO2025092985A1 (fr) * 2023-11-03 2025-05-08 合肥医工医药股份有限公司 Inhibiteur de phosphodiestérase 4b, son procédé de préparation et son utilisation
WO2026046267A1 (fr) * 2024-08-28 2026-03-05 石药集团中奇制药技术（石家庄）有限公司 Forme cristalline d'un dérivé de dihydrothiénopyrimidine et son utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (fr) 1972-12-18 1979-02-27 Affiliated Medical Research Pyridone n-substituee; methode generale de synthese des pyridones
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
EP1847543A1 (fr) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidines pour le traitement de maladies inflammatoires
EP1870400A1 (fr) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Sels et sels cristallines d'un produit 2-indolinone
JP5341899B2 (ja) 2007-10-19 2013-11-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロ環置換ピペラジノ−ジヒドロチエノピリミジン
ES2524910T3 (es) 2007-10-19 2014-12-15 Boehringer Ingelheim International Gmbh Piperidino-dihidrotienopirimidinas sustituidas
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
HRP20180709T1 (hr) 2008-06-06 2018-06-15 Boehringer Ingelheim International Gmbh Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) * 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2014124860A1 (fr) * 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Inhibiteurs spécifiques de pde4b pour le traitement du diabète sucré
CN106535896B (zh) * 2015-04-27 2019-06-21 江苏恒瑞医药股份有限公司 蛋白激酶抑制剂在制备治疗纤维化疾病的药物中的用途
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)

Also Published As

Publication number Publication date
CN111278442B (zh) 2023-06-06
EA202090977A1 (ru) 2020-09-04
JP2021500362A (ja) 2021-01-07
CN111278442A (zh) 2020-06-12
IL273169A (en) 2020-04-30
IL273169B2 (en) 2024-05-01
PL3700529T3 (pl) 2025-12-22
IL309150B1 (en) 2024-11-01
PH12020550452A1 (en) 2021-03-15
TWI700088B (zh) 2020-08-01
US20250241919A1 (en) 2025-07-31
IL273169B1 (en) 2024-01-01
KR102893133B1 (ko) 2025-12-02
ES3041129T3 (en) 2025-11-07
TW201929858A (zh) 2019-08-01
CL2020000627A1 (es) 2020-08-21
IL309150B2 (en) 2025-03-01
US11813266B2 (en) 2023-11-14
AU2018357775B2 (en) 2024-02-15
KR20200075864A (ko) 2020-06-26
AU2024203045B2 (en) 2026-02-19
BR112020003973A2 (pt) 2020-09-01
NZ762200A (en) 2024-10-25
FI3700529T3 (fi) 2025-09-18
RS67241B1 (sr) 2025-10-31
MX2020004173A (es) 2020-08-03
EP4603094A2 (fr) 2025-08-20
HUE072914T2 (hu) 2025-12-28
US20220378793A1 (en) 2022-12-01
KR20250172732A (ko) 2025-12-09
US20230405010A1 (en) 2023-12-21
EP3700529A1 (fr) 2020-09-02
SI3700529T1 (sl) 2025-10-30
AU2024203045A1 (en) 2024-05-23
AU2018357775A1 (en) 2020-03-19
US20190134043A1 (en) 2019-05-09
WO2019081235A1 (fr) 2019-05-02
LT3700529T (lt) 2025-10-10
DK3700529T3 (da) 2025-09-22
EP3700529B1 (fr) 2025-07-09
PT3700529T (pt) 2025-09-17
US12233068B2 (en) 2025-02-25
JP7196169B2 (ja) 2022-12-26
CA3079299A1 (fr) 2019-05-02
US11406638B2 (en) 2022-08-09
IL309150A (en) 2024-02-01
HRP20251042T1 (hr) 2025-10-24

Similar Documents

Publication Publication Date Title
MA50441A (fr) Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)
EP3642667C0 (fr) Lentille de contact d'orthokératologie pour le traitement de la myopie
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3267995A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3946357A4 (fr) Formulations topiques pour le traitement de neuropathies périphériques
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3434291A4 (fr) Composition pour le traitement d'un disque intervertébral
EP3634426A4 (fr) Compositions pour le traitement d'une fibrose
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3636252A4 (fr) Goutte ophtalmique pour le traitement de la sécheresse oculaire
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
MA53501A (fr) Inhibiteurs de pde9 pour le traitement de la drépanocytose
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA51738A (fr) Composés pour le traitement de la douleur
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose